# PT Etana Biotechnologies Indonesia

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pt-etana-biotechnologies-indonesia

- Industry: Biotechnology
- Headquarters: Jakarta, Indonesia
- Website: www.id.etanabiotech.com
- Latest round: Series B (Sep 27, 2022)
- Investors on record: 2

## About

Based in Jakarta, Indonesia, and founded in 2014, PT etana biotechnologies Indonesia operates as a biotechnology company that develops metabolic pharmaceuticals for the treatment of autoimmune diseases and cancer. In March 2023, PT Etana Biotechnologies Indonesia raised venture funding led by DEG, East Venture, HighLight Capital, and YF Capital. As of 2023, the company is led by its President director Nathan Tirtana. 

The firm offers various biopharmaceutical products which help in the treatment of various medical conditions which includes cancers, and metabolic and autoimmune diseases. As of 2022, It will produce epoetin alfa products which will be sold under the name of Renogen and could be used by patients undergoing dialysis treatment. It will also offer Bevagen which is a Bevacizumab biosimilar product that will be used for the treatment of advanced non-small cell lung cancer and metastatic colorectal cancer. The firm will produce monoclonal antibody drugs which will serve as substitute antibodies that can restore or enhance the immune system's attack on cancer cells.

The company plans to use the March 2023, funding to strengthen its pipeline and portfolio as well as its research and development in drug substances to increase product manufacturing.

## Funding rounds

- Series B, Sep 27, 2022 — YF Capital, HighLight Capital

## Investors

- YF Capital (https://capitalatlas.ai/funds/yf-capital) — Series B
- HighLight Capital (https://capitalatlas.ai/funds/highlight-capital) — Series B